Hormone replacement therapy in women with past history of endometriosis
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Endometriosis is a common clinical condition and its treatment will often lead to an estrogen deficiency status. As most of these patients are young, they will need to consider hormone replacement therapy. Endometriosis is a hormone-dependent disease and estrogen replacement can be associated with a risk of recurrence or malignant transformation. Only a few studies have addressed this problem. With the use of hormone replacement therapy (HRT), there is an increased, although undefined, risk of recurrence of endometriosis, especially in known severe cases and in obese patients. Unopposed estrogen appears to carry a higher risk than combined preparations. Delay in starting HRT after pelvic clearance is not of any benefit. After radical surgery for severe endometriosis, women often have much to gain from HRT, particularly in the early years. Benefits of HRT in terms of control of menopausal symptoms, prevention of urogenital atrophy and loss of libido and bone protection are of particular importance. HRT may still have a role in prevention of cardiovascular disease in early menopause, but this remains unproven. Although there is no firm evidence, continuous combined preparations or tibolone would appear to be the optimum choice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This approach induces iatrogenic premature or early menopause in these women who will need hormone replacement therapy (HRT) for many years until at least their natural age of menopause [4,5].”
From HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey (2023) · cites this paper as [5]
Citations
Cites
ENDOMETRIAL CARCINOMA OF THE OVARY, ARISING IN ENDOMETRIAL TISSUE IN THAT ORGAN
SAMPSON, J. A. (1925) · Archives of Surgery · doi:10.1001/archsurg.1925.01120100007001 · Cited by 765
Olive, D. L., & Schwartz, L. B. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282407 · Cited by 675
Age at menopause as a risk factor for cardiovascular mortality
van der Schouw, Y. T., van der Graaf, Y., Steyerberg, E. W., Eijkemans, M. J. C., & Banga, J. D. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90075-6 · Cited by 616
Cancer risk after a hospital discharge diagnosis of endometriosis
Brinton, L. A., Gridley, G., Persson, I., Baron, J., & Bergqvist, A. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70550-7 · Cited by 547
Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
Davis, S. R., McCloud, P., Strauss, B. J. G., & Burger, H. (1995) · Maturitas · doi:10.1016/0378-5122(94)00898-h · Cited by 533
Malignant neoplasms arising in endometriosis
Heaps, J., Nieberg, R., & Berek, J. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90262-4 · Cited by 393
Endometrial Cancer and Estrogen Use: Report of a Large Case-Control Study
Antunes, C. M. F., Stolley, P. D., Rosenshein, N. B., Davies, J. L., Tonascia, J. A., Brown, C., Burnett, L., Rutledge, A., Pokempner, M., & Garcia, R. (1979) · New England Journal of Medicine · doi:10.1056/nejm197901043000103 · Cited by 388
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Kalantaridou, S. N., Naka, K. K., Papanikolaou, E., Kazakos, N., Kravariti, M., Calis, K. A., Paraskevaidis, E. A., Sideris, D. A., Tsatsoulis, A., Chrousos, G. P., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0015 · Cited by 284
Research works printed but not linked: 12
- Kempers R D, 1960, Surg Gynaecol Oncol, 111, 348
- Schor E, 1999, Clin Exp Obstet Gynaecol, 26, 158
- Berguld A S, 2003, Hum Reprod, 18, 80
- Lauslahti K, 1972, Acta Pathol Microbiol Scand A, 80, 98
- Heaps J M, 1990, Obstet Gynecol, 75, 1023
- Granai C O, 1984, Obstet Gynecol, 64, 592
- Berkowitz R S, 1978, Obstet Gynecol, 51, 34
- Remnitz C, 1988, Obstet Gynecol, 1, 444
- Abu M AE, 1997, Eur J Gynecol Oncol, 18, 482
- Larvey S, 2001, Br J Obstet Gynaecol, 108, 1106
- Areia A, 2004, Eur J Gynaecol Oncol, 25, 225
- Beral V, 2005, Lancet, 30, 1543
Cited by
Endometriosis: Current Therapies and New Pharmacological Developments
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Barbara, G., & Crosignani, P. G. (2009) · Drugs · doi:10.2165/00003495-200969060-00002 · Cited by 182
“Soliman and Hillard[73] recently reviewed published data on this topic, and concluded that the available evidence does not suggest withholding hormone therapy from patients with hypoestrogenic symptoms.”
InfluentialOvarian cancer in endometriosis: molecular biology, pathology, and clinical management
Mandai, M., Yamaguchi, K., Matsumura, N., Baba, T., & Konishi, I. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0935-y · Cited by 162
“As mentioned above, estrogen, especially unopposed estrogen stimulation, may facilitate the malignant transformation of endometriotic cysts, though suffi cient evidence has not been shown yet.(53,59) In this regard, clinicians should carefully continue to follow up on cases of endometriosis, even after menopause, desp…”
BackgroundThe management of menopause in women with a history of endometriosis: A systematic review
Gemmell, L. C., Webster, K. E., Kirtley, S., Vincent, K., Zondervan, K. T., & Becker, C. M. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx011 · Cited by 154
“As a result, current recommendations favour continuous combined preparations instead of unopposed oestrogens for women with a history of endometriosis, but the evidence remains sparse (Soliman and Hillard, 2006; Oxholm et al., 2007).”
BackgroundEndometriosis: a premenopausal disease? Age pattern in 42,079 patients with endometriosis
Haas, D., Chvátal, R., Reichert, B., Renner, S. P., Shebl, O. J., Binder, H., Wurm, P., & Oppelt, P. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-012-2361-z · Cited by 166
“Although rare, endometriosis in the postmenopausal period has often been reported in association with hormone replacement therapy [22].”
BackgroundEndometriosis: current and future medical therapies
Vercellini, P., Somigliana, E., Viganò, P., Abbiati, A., Daguati, R., & Crosignani, P. G. (2007) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2007.10.001 · Cited by 150
Metadata
- Authors
- Soliman, N. F., & Hillard, T. C.
- Affiliations
- Yeovil District Hospital (GB)
- Poole Hospital (GB)
- Corresponding author
- Hillard, T. C.
- ORCID
- Hillard, T. C.
- Venue
- Climacteric
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 9
- Issue
- 5
- Pages
- 325-335
- ISSN
- 1369-7137 (ISSN-L)
- 1473-0804
- OpenAlex
- W2109120076
- Cited by
- 65
- References
- 70
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 4 · 2012: 4
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Climacteric (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- hormone replacement therapy, endometriosis, estrogen deficiency, endometriosis recurrence, malignant transformation, unopposed estrogen, combined estrogen-progestogen therapy, tibolone, menopausal symptoms, urogenital atrophy, bone protection, cardiovascular disease prevention, early menopause, obesity
- MeSH terms
- Adult, Aged, Endometriosis, Female, Humans, Hysterectomy, Menopause, Middle Aged, Norpregnenes, Risk Factors, Estrogen Replacement Therapy, Endometrial Neoplasms, Estrogen Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hormone replacement therapy in women with past history of endometriosis. https://app.cochat.ai/papers/10.1080/13697130600868711
- The paper
- Soliman, N. F., & Hillard, T. C. (2006). Hormone replacement therapy in women with past history of endometriosis. Climacteric. https://doi.org/10.1080/13697130600868711
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.